Live Breaking News & Updates on Harpoon Intermediate Level|Page 6
Stay updated with breaking news from Harpoon intermediate level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merck & Co is in advanced talks to buy cancer drugmaker Harpoon Therapeutics Inc for around $700 million, Bloomberg News reported on Sunday, citing people familiar with the matter. Merck is discussing paying $23 per share for immuno-oncology company Harpoon, Bloomberg said, representing a premium of 118% to Harpoon's Friday closing price of $10.55. A deal could be announced within days assuming talks don't fall apart, the report added. ....
US multinational pharmaceutical company Merck & Co is in talks with cancer drug maker Harpoon Therapeutics, to acquire Harpoon for an approximate total equity value of $680 million. Merck and Harpoon have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share. Harpoon's lead candidate, HPN328, is currently being evaluated in a Phase 1/2 clinical trial. Merck expects to record a charge of approximately $650 million, or approximately ....
Merck (MRK) and Harpoon Therapeutics, Inc. (HARP) have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23. ....
Ukraine is developing a “long” version of its ground-launched Neptune cruise missile one of its main weapons for striking Russian forces deep behind the front line. ....